HIV/AIDS
- Leveraging Experience From Active TB Drug-Safety Monitoring and Management for Monitoring Active Antiretroviral Toxicity
Systems established for active drug safety monitoring and management of drug-resistant TB should be leveraged to ensure comprehensive surveillance for active toxicity monitoring during scale-up of newer antiretroviral regimens.
- Implementation of HIV Retesting During Pregnancy and Postpartum in Kenya: A Cross-Sectional Study
Strategies are needed to prevent missed opportunities to detect women with incident HIV infection during pregnancy or postpartum and maximize prevention of mother-to-child HIV transmission efforts.
- Uptake and Short-Term Retention in HIV Treatment Among Men in South Africa: The Coach Mpilo Pilot Project
In this pilot project, providing peer support to men living with HIV retained a high proportion of men living with HIV in the early stages of HIV treatment and successfully supported men in returning to care after a treatment interruption.
- How Home Delivery of Antiretroviral Drugs Ensured Uninterrupted HIV Treatment During COVID-19: Experiences From Indonesia, Laos, Nepal, and Nigeria
During the COVID-19 pandemic, home delivery of antiretrovirals for HIV treatment proved to be a feasible approach for ensuring treatment continuation amid facility closures and travel restrictions. Antiretroviral home delivery is a model warranting further consideration as an additional option for decentralized drug delivery for HIV treatment.
- A Quality Improvement Intervention to Inform Scale-Up of Integrated HIV-TB Services: Lessons Learned From KwaZulu-Natal, South Africa
Despite being standard of care, gaps in HIV-TB service delivery are present. Quality Improvement methods are effective in uncovering health systems weaknesses that impede efficient delivery of integrated HIV-TB services.
- A Mixed-Methods Process Evaluation: Integrating Depression Treatment Into HIV Care in Malawi
Effectively integrating depression treatment into HIV care in low-resource settings will require substantially investing in program supervision, building and maintaining the capacity of providers, integrating into existing electronic medical records systems, and ensuring the availability of psychotherapy counselors.
- Differentiated Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A Landscape Analysis
Observing the diversity of differentiated service delivery models for HIV treatment in use in sub-Saharan Africa can help policy makers and program planners to improve decision making for treatment delivery in the future. This effort can inform decisions about how to optimize the distribution of models across facilities and regions and how to plan for budget and resource allocation.
- Improving Services for HIV-Exposed Infants in Zambia and Cameroon Using a Quality Improvement Collaborative Approach
To bridge the gap between what is known and what is done, quality improvement collaboratives (QICs) enable health programs to rapidly address quality challenges at scale. Two QICs in Cameroon and Zambia improved coverage of early infant HIV testing and initiating antiretroviral therapy in HIV-exposed infants. The QIC approach empowers health care workers to design solutions tailored for their specific settings.
- Pathways to Care for Patients With Type 2 Diabetes and HIV/AIDS Comorbidities in Soweto, South Africa: An Ethnographic Study
Patients with type 2 diabetes are referred to tertiary hospitals in Soweto although their care could be managed at primary health care clinics. Primary health care needs to be strengthened by addressing health systemic challenges to provide integrated care for comorbid type 2 diabetes and HIV/AIDS.
- Inpatient Point-of-Care HIV Early Infant Diagnosis in Mozambique to Improve Case Identification and Linkage to Antiretroviral Therapy
Introduction of point-of-care early infant diagnosis on the inpatient wards of 2 of the largest pediatric referral hospitals in Mozambique increased HIV testing volume and pediatric HIV case identification with improved linkage to antiretroviral therapy.